Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly And AC Immune Partner On A Small Molecule With Potential In Alzheimer's Combinations

Executive Summary

Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q4 2018
Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs
Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel